4 terminated. 4 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Terminated 4 |
| Phase 2 | 3 | Terminated 3 |
Follow Fabry Disease: new trials by email Literature Review of Fabry Disease trials Research Report on Fabry Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190 FLT190 - Fabry Disease, Lysosomal Storage Diseases | Phase 1 / Phase 2 | Terminated | Spur Therapeutics | 3 | 2020-09-08 | 2026-09-03 |
| A Fabry Disease Gene Therapy Study FLT190 - Fabry Disease, Lysosomal Storage Diseases | Phase 1 / Phase 2 | Terminated | Spur Therapeutics | 3 | 2019-07-08 | 2026-09-03 |
| Open Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment-Naive Subjects With Classic Fabry Disease AVR-RD-01 - Fabry Disease | Phase 1 / Phase 2 | Terminated | AVROBIO | 15 | 2018-02-21 | 2024-01-05 |
| A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease Iohexol - Fabry Disease | Phase 1 | Terminated | Genzyme, a Sanofi Company | 39 | 2013-05-01 | 2020-12-16 |
Lysosomal Storage Diseases (3)
Brain Diseases (4) · Brain Diseases, Metabolic (4) · Brain Diseases, Metabolic, Inborn (4) · Cardiovascular Diseases (4) · Central Nervous System Diseases (4) · Cerebral Small Vessel Diseases (4) · Cerebrovascular Disorders (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Genetic Diseases, Inborn (4) · Genetic Diseases, X-Linked (4) · Lipid Metabolism Disorders (4) · Lipid Metabolism, Inborn Errors (4) · Lipidoses (4) · Lysosomal Storage Diseases, Nervous System (4) · Metabolic Diseases (4)
Iohexol (1)
Spur Therapeutics (2) · AVROBIO (1) · Genzyme, a Sanofi Company (1)
United Kingdom (3) · United States (3) · Austria (2) · Brazil (2) · Canada (2) · Germany (2) · Norway (2) · Argentina (1) · Australia (1) · Belgium (1) · Finland (1) · France (1) · Hungary (1) · Italy (1) · Poland (1)
Inderpal Panesar, MRPharmS (1)